Recent Advances in Molecular Diagnosis and Prognosis of Childhood B Cell Lineage Acute Lymphoblastic Leukemia (B-ALL)Cytogenetic risk groupsCopy number alterationsTargeted therapyB cell lineage acute lymphoblastic leukemia is the most common leukemia occurring in children and young adults and is the ...
10. Roberts, K. G. Genetics and prognosis of ALL in children vs adults. Hematology Am. Soc. Hematol. Educ. Program 2018, 137–145 (2018). 11. Lestienne,C.R.,Diagnosis of intrachromosomal amplification of chromosome 21 (iA...
Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360:470-480; Stanulla M, Dagdan E,Zaliova M, et al. IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell ...
ABSTRACT B-lineage Acute Lymphoblastic Leukemia (B-ALL) in the elderly population is generally considered to have a poor prognosis. It is unclear if their survival has improved in the current era. Using Surveillance Epidemiolo...
In the pediatric population, B-acute lymphoblastic leukemia (B-ALL) is the most prevalent childhood hematological malignancy, as well as the leading cause of childhood cancer-related mortality. Advances in cytogenetics utilizing array-based technologies and next-generation sequencing (NGS) techniques hav...
(1)探讨成人B系急性淋巴细胞白血病(B-ALL)的临床与生物学特征,分析其与临 床预后的关系,进一步为成人B-ALL患者的分层治疗提供依据。 (2)对我院66例行异基因造血干细胞(allo-HSCT)的成人Ph + ALL患者进行临床观 察,对比分析临床疗效,探讨其治疗策略。
1.1.4 复发或进展后挽救性治疗对于急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)、急性髓细胞性白血病(acute myeloid leukemia,AML),目前证据等级最高的预防复发的手段为直接桥接异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT),通过不同靶点CAR-T细胞序贯输注或者双靶点CAR-T...
[8]Ting S, Mixue X, Lixia Z, et al. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes....
Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients relapse with CD19(−) disease. We report that CD19(−) escape is associated with downregulation, but preservat...
Recent data show that B cells and plasma cells located in tumours or in tumour-draining lymph nodes can have important roles in shaping antitumour immune responses. In tumour-associated tertiary lymphoid structures, T cells and B cells interact and under